List of Excipients in Branded Drug AGRYLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Takeda Pharmaceuticals America Inc	AGRYLIN	anagrelide hydrochloride	54092-063	ANHYDROUS LACTOSE
Takeda Pharmaceuticals America Inc	AGRYLIN	anagrelide hydrochloride	54092-063	CELLULOSE, MICROCRYSTALLINE
Takeda Pharmaceuticals America Inc	AGRYLIN	anagrelide hydrochloride	54092-063	CROSPOVIDONE
Takeda Pharmaceuticals America Inc	AGRYLIN	anagrelide hydrochloride	54092-063	LACTOSE MONOHYDRATE

AGRYLIN Excipient Strategy and Commercial Opportunities for Anagrelide

Last updated: September 1, 2026

AGRYLIN is the U.S. brand for anagrelide hydrochloride, an oral platelet-lowering drug used to treat thrombocythemia associated with myeloproliferative neoplasms. The commercial opportunity is primarily generic differentiation rather than restoration of brand exclusivity. The strongest excipient opportunities are dose-uniformity control, lactose-free positioning, improved swallowability, pediatric or dysphagia-friendly delivery, and differentiated packaging for chronic use.

What is AGRYLIN and how does its formulation compete?

AGRYLIN is supplied as immediate-release capsules in 0.5 mg and 1 mg strengths. Anagrelide reduces platelet production through inhibition of megakaryocyte maturation. The drug is used mainly in essential thrombocythemia and related myeloproliferative disorders.[1]

Attribute	AGRYLIN
Active ingredient	Anagrelide hydrochloride
Therapeutic class	Platelet-lowering agent
Dosage form	Immediate-release hard capsules
U.S. strengths	0.5 mg and 1 mg
Administration	Oral
Primary indication	Reduction of elevated platelet counts in patients with myeloproliferative neoplasms
Key safety constraints	Cardiovascular effects, headache, gastrointestinal effects, bleeding risk, hepatic and renal considerations
U.S. regulatory pathway	NDA product with multiple generic opportunities
Biosimilar relevance	None; anagrelide is a small molecule

AGRYLIN does not compete in a conventional high-volume primary-care market. Demand is concentrated among patients with rare hematologic disorders, hematology practices, specialty pharmacies, hospitals, and long-term maintenance users. This favors reliable supply, patient adherence, and reimbursement access over high-cost formulation innovation.

What excipients are used in AGRYLIN capsules?

The FDA-approved labeling identifies inactive ingredients used in AGRYLIN capsules, including lactose anhydrous, povidone, crospovidone, magnesium stearate, sodium lauryl sulfate, colloidal silicon dioxide, gelatin, and titanium dioxide.[1] Exact capsule-shell colorants and excipient quantities may vary by strength, manufacturing site, and labeling revision.

Excipient category	Likely function in AGRYLIN
Lactose anhydrous	Diluent and capsule-fill mass
Povidone	Binder and granulation aid
Crospovidone	Superdisintegrant
Magnesium stearate	Lubricant
Colloidal silicon dioxide	Glidant and flow aid
Sodium lauryl sulfate	Wetting or dissolution-support agent
Gelatin	Capsule shell
Titanium dioxide and colorants	Opacity and product identification

The formulation is technically conventional. The commercial significance lies in the very low dose of anagrelide relative to the total capsule fill. A 0.5 mg strength creates greater sensitivity to blending, segregation, assay variability, and content uniformity than a higher-dose solid oral product.

Why does the low dose matter?

Anagrelide represents a small fraction of the total capsule mass. The formulator must control:

• Active distribution throughout the powder blend.
• Losses during transfer and encapsulation.
• Electrostatic segregation.
• Sampling error during content-uniformity testing.
• Dissolution performance across both strengths.
• Stability under routine warehouse conditions.

A direct-compression formulation may be commercially attractive because it reduces processing steps, but it can create greater risk of segregation if particle size, density, and flow behavior are not tightly controlled. Wet granulation or dry granulation can improve blend uniformity, although those processes increase validation and manufacturing complexity.

What excipient strategy is most attractive for a generic AGRYLIN product?

The highest-probability strategy is a bioequivalent immediate-release capsule with a simpler, more patient-friendly excipient profile. A developer should prioritize regulatory execution and supply reliability before pursuing a novel dosage form.

Lactose-free formulation

A lactose-free product is the clearest excipient-led differentiation. AGRYLIN labeling identifies lactose anhydrous as an inactive ingredient.[1] Replacing lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, starch, or a composite filler could support:

• Use in patients avoiding lactose.
• Simplified institutional formulary review.
• Cleaner labeling for specialty pharmacies.
• Differentiation among otherwise interchangeable generics.

The main technical issue is maintaining powder flow, capsule fill weight, dissolution, and content uniformity after changing filler density and particle morphology. Mannitol can improve mouthfeel but may alter hygroscopicity and compaction behavior. Microcrystalline cellulose can improve compactability but may produce a different fill-volume profile.

Low-excipient and allergen-conscious formulation

A formulation that removes sodium lauryl sulfate, gelatin, or selected colorants could target patients with excipient sensitivities or dietary preferences. A vegetarian or hydroxypropyl methylcellulose capsule shell could provide a marketing distinction, although the commercial value is likely limited unless paired with broader pharmacy-channel demand.

The regulatory burden is manageable for an ANDA if the formulation meets sameness or permissible difference requirements and demonstrates bioequivalence. The product would still require careful review of the inactive ingredient levels and the FDA Inactive Ingredient Database.[2]

Improved content uniformity

Content uniformity is the most important technical opportunity. Potential approaches include:

• Pre-blending anagrelide with a small-volume carrier.
• Particle-size engineering of the drug substance.
• Geometric dilution before high-shear blending.
• Ordered mixing using carrier particles.
• Roller compaction with validated segregation controls.
• In-line or at-line blend monitoring.
• Tighter controls on capsule-fill weight.

This strategy may not be visible to prescribers, but it can reduce batch failures, improve manufacturing yield, and support a more robust ANDA product.

Capsule-shell redesign

A hard hypromellose capsule could remove animal-derived gelatin and improve suitability for selected patient populations. Color and imprint changes must preserve product identification and reduce medication-error risk.

A clear or lightly colored capsule could support visual inspection, but opaque shells may provide better protection from light. The selection depends on anagrelide’s stability profile, packaging system, and photostability data.

What formulations are protected or commercially available for anagrelide?

The established U.S. product is an immediate-release capsule. The principal formulation categories are:

Formulation concept	Commercial status	Opportunity
Immediate-release gelatin capsule	Established by AGRYLIN and generics	Lowest regulatory risk
Lactose-free capsule	Potential generic differentiation	Moderate opportunity
Hypromellose capsule	Potential generic differentiation	Niche opportunity
Sprinkle capsule	Limited development precedent	Adherence opportunity
Oral liquid	Not the standard commercial presentation	Pediatric and dysphagia opportunity
Extended-release product	No established dominant product	Higher development and clinical risk
Orally disintegrating tablet	Uncertain commercial demand	Limited opportunity
Compounded suspension	Possible pharmacy service	Low scalability and variable economics

A modified-release product would have greater commercial differentiation, but it could also change the pharmacokinetic profile and require more extensive clinical development. Anagrelide’s cardiovascular and gastrointestinal adverse effects make uncontrolled changes in peak concentration commercially risky.

When does AGRYLIN lose exclusivity?

AGRYLIN no longer has a meaningful U.S. market-exclusivity barrier based on new chemical entity protection. The product was approved in the 1990s, and generic anagrelide capsules are commercially available in the United States.[1,3]

Exclusivity issue	Current assessment
NCE exclusivity	Expired
U.S. patent barrier	No apparent commercially decisive barrier to generic capsule entry
Generic availability	Yes
Paragraph IV relevance	Relevant only to any later-listed, unexpired Orange Book patent
Biosimilar exclusivity	Not applicable
Brand-only market period	Ended

A live patent assessment should distinguish between composition-of-matter, formulation, method-of-use, manufacturing, and packaging claims. For a mature small-molecule product with approved generics, the practical focus is usually on formulation economics and supply-chain execution rather than Orange Book litigation.

What is the Orange Book status of AGRYLIN?

The FDA Orange Book is the controlling source for listed patents, exclusivity, therapeutic equivalence codes, and reference-product information.[3] AGRYLIN is a small-molecule reference product evaluated through the ANDA pathway. Generic anagrelide capsules generally compete through therapeutic-equivalence determinations rather than biosimilar licensing.

Paragraph IV challenges

Paragraph IV litigation is most relevant if a generic applicant certifies that an unexpired listed patent is invalid, unenforceable, or will not be infringed. For AGRYLIN, the age of the product and existing generic competition reduce the likelihood that an old core-product patent remains a material barrier.

A later formulation, dosing, or method-of-use patent could still create a narrow legal dispute. Such a patent would not necessarily block all generic capsule sales if the generic label omits the patented use or if the patent is not listed in a manner that supports a statutory stay.

Method-of-use patents

Method-of-use claims may cover platelet-count reduction, dosing regimens, patient selection, or treatment of a specific myeloproliferative condition. Their commercial value depends on:

• Whether the indication appears in the generic label.
• Whether the patented use is commercially important.
• Whether physicians can prescribe the drug for non-patented uses.
• Whether an ANDA applicant uses a skinny-label strategy.
• Whether induced-infringement evidence exists.

For anagrelide, method-of-use protection is more likely to affect a narrow indication or dosing practice than the overall market for immediate-release capsules.

How strong is the AGRYLIN patent estate?

The practical patent estate is weak as a barrier to conventional generic entry but may still leave room for narrow improvement patents.

Patent-estate dimension	Assessment
Core molecule	Mature and commercially exposed
Immediate-release capsule	Generic competition established
Novel excipient platform	Potentially protectable if tied to measurable performance
Modified release	Potentially differentiated but clinically and regulatorily demanding
Manufacturing process	Possible protection, but difficult to enforce against undisclosed processes
Method of use	Narrower protection and label-dependent
Packaging and adherence	Usually limited patent value unless technically novel

The strongest new patent position would likely require more than replacing lactose with another filler. A defensible formulation patent would need a specific composition, concentration range, manufacturing process, or performance result that is not predictable from routine formulation practice.

Potentially valuable claims could cover:

• Anagrelide particle-size distributions linked to content uniformity.
• A low-dose blend with defined carrier and disintegrant ratios.
• A lactose-free formulation with controlled dissolution.
• A capsule composition that limits degradation under defined humidity conditions.
• A sprinkle formulation with acceptable stability and bioequivalence.
• A pediatric suspension with validated dose uniformity and chemical stability.

What commercial opportunities exist for AGRYLIN excipients?

Specialty generic launch

The most practical opportunity is a generic 0.5 mg and 1 mg capsule with:

• Competitive acquisition cost.
• Reliable dual-source manufacturing.
• Lactose-free positioning.
• Standardized capsule appearance.
• Strong content-uniformity controls.
• Specialty-pharmacy distribution.

The 0.5 mg capsule should receive priority because it presents the greater manufacturing challenge and is central to dose titration.

Hospital and specialty-pharmacy contracting

Hematology products are often evaluated on supply continuity, back orders, recalls, and substitution rules. A supplier that can demonstrate stable availability may win business even without a novel dosage form.

A differentiated excipient profile can support formulary messaging, but purchasing decisions will remain highly price-sensitive after generic entry.

Patient-adherence products

Anagrelide may require individualized dosing and monitoring. A formulation that reduces swallowing difficulty or supports flexible administration could improve persistence. Candidate products include:

• Smaller capsules.
• Hypromellose capsules.
• Sprinkle capsules.
• A pharmacist-dispensed oral suspension.
• Calendar packaging with dose-strength separation.

Any product that changes administration instructions must be supported by stability, dose-recovery, and bioequivalence data.

Compounding and oral-liquid supply

An oral liquid could address patients unable to swallow capsules, including selected elderly, neurologically impaired, or pediatric patients. The opportunity is more likely to fit a specialty-compounding or hospital-manufacturing model than a broad retail product.

The key development risks are:

• Anagrelide solubility.
• Chemical stability in aqueous media.
• Adsorption to containers and tubing.
• Uniformity after storage.
• Preservative compatibility.
• Dose measurement accuracy.
• Occupational handling controls.

A liquid product would need clear beyond-use or in-use instructions and packaging that minimizes dosing errors.

What manufacturing and IP barriers affect anagrelide products?

Anagrelide manufacturing requires control of low-dose blending and capsule filling. The primary barriers are operational rather than molecule-specific.

Manufacturing barriers

• Low active-load content uniformity.
• Blend segregation during transfer.
• Variable powder flow.
• Capsule-fill weight control.
• Moisture sensitivity of the drug-excipient system.
• Stability of the final capsule.
• Supply of qualified anagrelide hydrochloride API.
• Validation of cleaning and cross-contamination controls.

Intellectual-property barriers

A developer should separate patentability from freedom to operate. A new excipient combination may be patentable but still overlap with broad formulation claims. Conversely, a commercially useful process may be difficult to detect in a competitor’s manufacturing operation.

Trade-secret protection may be more practical for:

• Blend-order controls.
• Granulation endpoint parameters.
• API particle engineering.
• Encapsulation settings.
• Packaging and humidity controls.

How does AGRYLIN compare with competing platelet-lowering drugs?

Product	Active ingredient	Dosage form	Excipient opportunity	Competitive position
AGRYLIN	Anagrelide	Immediate-release capsule	Lactose-free, low-dose uniformity, swallowability	Established generic market
Hydroxyurea	Hydroxyurea	Capsule/tablet	Lower-cost oral solid alternatives	Broad hematology use
Interferon products	Various interferons	Injectable	Device and formulation differentiation	Higher administration burden
Ruxolitinib	Ruxolitinib	Tablet	Dose flexibility and adherence	Different mechanism and market segment
Busulfan	Busulfan	Tablet/injection	Limited overlap	Narrower use and different toxicity profile

Anagrelide’s main commercial advantage is oral administration and a mechanism distinct from cytoreductive agents such as hydroxyurea. Its disadvantages include cardiovascular monitoring, gastrointestinal tolerability, and a smaller patient population.

What generic launch scenarios exist for anagrelide?

Base-case scenario

A conventional 0.5 mg and 1 mg immediate-release capsule enters or expands in the generic market. Price competition increases, while supply reliability and wholesaler access determine share.

Differentiated-generic scenario

A lactose-free or hypromellose-capsule product gains limited specialty-pharmacy and prescriber attention. The product may support modest price preservation but is unlikely to create durable premium pricing without clinical or adherence evidence.

Specialty-delivery scenario

A sprinkle capsule or stable oral liquid targets dysphagia and pediatric use. This could create a defensible niche, but development costs and clinical requirements would be higher.

Risk scenario

A reformulated product produces different exposure, dissolution, or adverse-event patterns. Cardiovascular tolerability concerns could undermine adoption and trigger regulatory scrutiny.

Key Takeaways

• AGRYLIN is an established immediate-release anagrelide capsule in 0.5 mg and 1 mg strengths.
• U.S. exclusivity has expired, and generic competition is established.
• The most important formulation challenge is content uniformity at a very low active-drug load.
• Lactose-free and hypromellose-capsule formulations are the clearest excipient-led opportunities.
• A novel oral liquid or sprinkle product could address dysphagia and pediatric use but carries greater development risk.
• Modified release would create stronger differentiation but would require a more demanding pharmacokinetic and clinical strategy.
• Method-of-use and formulation patents may protect narrow improvements, but they are unlikely to block the mature immediate-release market by themselves.
• Commercial success will depend more on API supply, manufacturing yield, quality consistency, reimbursement, and specialty-pharmacy distribution than on minor excipient changes.

FAQs About AGRYLIN Excipient and Commercial Strategy

Can a lactose-free anagrelide capsule be approved as an ANDA?

Yes. A lactose-free capsule may be submitted through the ANDA pathway if it meets applicable formulation requirements and demonstrates bioequivalence to the reference product. The inactive ingredients must comply with FDA requirements and be supported by appropriate safety and quality data.[2,4]

Is anagrelide suitable for an extended-release formulation?

Potentially, but the commercial case is uncertain. Extended release could reduce peak-related adverse effects or dosing frequency, yet it would require proof that altered exposure does not reduce platelet control or increase cardiovascular risk.

Could anagrelide be developed as a pediatric oral liquid?

Yes, an oral liquid could address swallowing and dose-flexibility needs. Development would focus on solubility, stability, dose uniformity, container compatibility, and clinical acceptability.

Do anagrelide generics face biosimilar competition?

No. Anagrelide is a chemically synthesized small molecule. Competition proceeds through generic-drug pathways, principally ANDAs, rather than the biologic biosimilar pathway.

What is the strongest patent opportunity for a new anagrelide product?

The strongest opportunity is a technically differentiated formulation tied to measurable performance, such as improved low-dose content uniformity, controlled dissolution, enhanced stability, or a validated sprinkle or liquid presentation. A routine filler substitution alone is less likely to support a durable patent position.

References

1. U.S. Food and Drug Administration. (n.d.). AGRYLIN (anagrelide hydrochloride) capsules prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin: Guidance for industry.